Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Matthew Davids, MD
Conference Coverage
Genetic Risk Factors May Help Predict Richter Transformation in Chronic Lymphocytic Leukemia
01/05/2026
Matthew S. Davids, MD, MMSc
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights...
01/05/2026
Oncology
Wojciech Jurczak, MD, PhD
Conference Coverage
Frontline Pirtobrutinib Shows Superior PFS vs Bendamustine-Rituximab for CLL/SLL: BRUIN CLL-313 Trial
12/15/2025
Wojciech Jurczak, MD, PhD
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from...
12/15/2025
Oncology
Catherine Coombs, MD
Conference Coverage
Evolving Treatment Strategies for Patients With Chronic Lymphocytic Leukemia
06/28/2025
Catherine Coombs, MD
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting , Catherine Coombs, MD, discussed insights into evolving treatment strategies for patients with chronic lymphocytic leukemia.
At the 2025 Great Debates in...
06/28/2025
Oncology
Constantine Tam, MD
Conference Coverage
Zanubrutinib for Patients With del(17p) CLL and SLL: 5-Year Follow-Up From the SEQUOIA Trial
06/03/2025
Constantine S. Tam
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses 5-year follow-up results from the SEQUOIA trial evaluating the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and a chromosome 17p deletion.
Constantine Tam, MD discusses...
06/03/2025
Oncology
John Allan, MD
Videos
Novel Targeted Therapies for Patients With Chronic Lymphocytic Leukemia
02/24/2025
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new...
02/24/2025
Oncology
Matthew Davids, MD, MMSc
Videos
Strategies for Approaching BTK Inhibitor Resistance and Mutations Among Patients With Chronic Lymphocytic Leukemia
02/09/2025
Matthew S. Davids, MD, MMSc
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia &...
02/09/2025
Oncology
Craig Sauter, MD
Conference Coverage
Exploring CAR T-Cell Therapy for Aggressive Lymphomas Including DLBCL and CLL/SLL With Richter’s Transformation
10/18/2024
Craig Sauter, MD
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Oncology
Erin Wiedmeier-Nutor, MD
Videos
Targeted DNA Sequencing for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
Erin Wiedmeier-Nutor, MD, discusses study results that compare a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations with a fluorescence in situ hybridization panel among untreated patients...
Erin Wiedmeier-Nutor, MD, discusses study results that compare a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations with a fluorescence in situ hybridization panel among untreated patients...
Erin Wiedmeier-Nutor, MD,...
10/15/2024
Oncology
Kerry Rogers, MD
Conference Coverage
Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?
09/23/2024
Kerry Rogers, MD
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry...
09/23/2024
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use